ESMO Congress 2020

The current evidence suggests that a large proportion of patients not responding to PD-1/PD-L1-targeted agents do not have PD-L1-expressing tumours

Lectures from this year’s ESMO awards recipients kick off the week leading up to the Education weekend of the ESMO Virtual Congress 2020

A key advance in the fight against cancer is the availability of multiple treatment modalities developed to target different aspects of tumourigenesis and maintenance of cancer

At ESMO Virtual Congress 2020, the first report of clinical responses in multiple solid tumour subtypes increases knowledge on safety of tumour-infiltrating lymphocyte-based adoptive cell therapy combined with immunotherapy.

Immunotherapy as second- and third-line treatment is effective in pre-treated malignant pleural mesothelioma

Presentations at ESMO Virtual Congress 2020 gave insights into the impact of COVID-19 on cancer management, cancer research and the healthcare professionals involved, which can help to prepare for future crises.

Study design still seems to be a major limitation to translate promising approaches in rare cancers, as negative trials presented at the ESMO Virtual Congress 2020 show.

Encouraging data from phase I and II studies in pre-treated adult patients but not in children where prognosis is poor.

Findings from early clinical trials at the ESMO Virtual Congress 2020 are encouraging for the use of precision medicine in adenoid cystic carcinoma and salivary gland carcinoma

In the LEAP-004 study presented at the ESMO Virtual Congress 2020, ORR is encouraging but survival results are difficult to interpret.